MX2017005042A - Formas de dosificacion oral de magnesio de liberacion controlada, de alta carga y metodos para elaborar y utilizar las mismas. - Google Patents
Formas de dosificacion oral de magnesio de liberacion controlada, de alta carga y metodos para elaborar y utilizar las mismas.Info
- Publication number
- MX2017005042A MX2017005042A MX2017005042A MX2017005042A MX2017005042A MX 2017005042 A MX2017005042 A MX 2017005042A MX 2017005042 A MX2017005042 A MX 2017005042A MX 2017005042 A MX2017005042 A MX 2017005042A MX 2017005042 A MX2017005042 A MX 2017005042A
- Authority
- MX
- Mexico
- Prior art keywords
- magnesium
- methods
- dosage forms
- oral dosage
- prepare
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000006186 oral dosage form Substances 0.000 title abstract 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052749 magnesium Inorganic materials 0.000 title abstract 2
- 239000011777 magnesium Substances 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 abstract 3
- 159000000003 magnesium salts Chemical class 0.000 abstract 3
- 239000002552 dosage form Substances 0.000 abstract 2
- 208000008167 Magnesium Deficiency Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000004764 magnesium deficiency Nutrition 0.000 abstract 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 abstract 1
- 229960004658 magnesium lactate Drugs 0.000 abstract 1
- 235000015229 magnesium lactate Nutrition 0.000 abstract 1
- 239000000626 magnesium lactate Substances 0.000 abstract 1
- 229940091250 magnesium supplement Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen formas de dosificación de alta carga, de liberación controlada para administración oral de sales de magnesio. Por ejemplo, una forma de dosificación oral puede comprender desde aproximadamente 80% hasta aproximadamente 95% de lactato de magnesio y uno o más componentes. Como otro ejemplo, una forma de dosificación oral puede comprender por lo menos aproximadamente 50% de sal de magnesio y exhibe un perfil de disolución de liberación controlada. También se describen métodos para elaborar formas de dosificación de liberación controlada para administración oral de una cantidad terapéuticamente efectiva de sal de magnesio a un mamífero. También se describen métodos para tratar un trastorno caracterizado por deficiencia de magnesio y métodos para prevenir o aliviar bajos niveles de magnesio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/132,461 US9707253B2 (en) | 2008-05-19 | 2016-04-19 | High-loading, controlled-release magnesium oral dosage forms and methods for making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017005042A true MX2017005042A (es) | 2018-08-20 |
| MX375905B MX375905B (es) | 2025-03-07 |
Family
ID=58578872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005042A MX375905B (es) | 2016-04-19 | 2017-04-18 | Formas de dosificacion oral de magnesio de liberacion controlada, de alta carga y metodos para elaborar y utilizar las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3243507A1 (es) |
| JP (1) | JP2017214352A (es) |
| KR (1) | KR20170119651A (es) |
| AR (1) | AR108235A1 (es) |
| AU (1) | AU2017202534B1 (es) |
| CA (1) | CA2964581C (es) |
| CL (1) | CL2017000957A1 (es) |
| MX (1) | MX375905B (es) |
| MY (1) | MY185460A (es) |
| RU (1) | RU2017113518A (es) |
| SG (1) | SG10201703206TA (es) |
| ZA (1) | ZA201702773B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201800011125A1 (it) * | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
| EP4212149A1 (en) | 2022-01-18 | 2023-07-19 | Rijksuniversiteit Groningen | Oral dosage forms of acid-labile salt and methods and uses related thereto |
| CN116421580A (zh) * | 2023-04-21 | 2023-07-14 | 杭州高成生物营养技术有限公司 | 柠檬酸镁缓释小丸及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002774A (en) * | 1989-06-08 | 1991-03-26 | Erbamont, Inc. | Sustained release pharmaceutical tablet |
| WO2009143072A1 (en) * | 2008-05-19 | 2009-11-26 | Wynden Pharmaceuticals, Inc. | High-loading, controlled-release magnesium oral dosage forms and methods of making and using same |
-
2017
- 2017-04-17 JP JP2017081314A patent/JP2017214352A/ja active Pending
- 2017-04-17 MY MYPI2017000564A patent/MY185460A/en unknown
- 2017-04-18 MX MX2017005042A patent/MX375905B/es active IP Right Grant
- 2017-04-18 EP EP17166926.0A patent/EP3243507A1/en not_active Ceased
- 2017-04-18 CA CA2964581A patent/CA2964581C/en active Active
- 2017-04-18 CL CL2017000957A patent/CL2017000957A1/es unknown
- 2017-04-18 AU AU2017202534A patent/AU2017202534B1/en active Active
- 2017-04-19 SG SG10201703206TA patent/SG10201703206TA/en unknown
- 2017-04-19 ZA ZA2017/02773A patent/ZA201702773B/en unknown
- 2017-04-19 KR KR1020170050614A patent/KR20170119651A/ko not_active Withdrawn
- 2017-04-19 RU RU2017113518A patent/RU2017113518A/ru not_active Application Discontinuation
- 2017-04-19 AR ARP170100997A patent/AR108235A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX375905B (es) | 2025-03-07 |
| SG10201703206TA (en) | 2017-11-29 |
| CA2964581A1 (en) | 2017-10-19 |
| RU2017113518A (ru) | 2018-10-19 |
| ZA201702773B (en) | 2018-11-28 |
| EP3243507A1 (en) | 2017-11-15 |
| MY185460A (en) | 2021-05-19 |
| AU2017202534B1 (en) | 2017-06-08 |
| JP2017214352A (ja) | 2017-12-07 |
| KR20170119651A (ko) | 2017-10-27 |
| AR108235A1 (es) | 2018-08-01 |
| CL2017000957A1 (es) | 2017-12-15 |
| CA2964581C (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| CL2020000215A1 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. | |
| CO2021006075A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| CL2018000429A1 (es) | Moduladores de la expresión de kras | |
| MX2019007586A (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| MX390503B (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
| MX2022007221A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
| BR112017017078A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença. | |
| CL2015003442A1 (es) | Derivados heterociclicos | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| EA201691872A1 (ru) | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
| BR112017015852A2 (pt) | forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1 | |
| EA201691881A1 (ru) | Новые соединения | |
| JO3789B1 (ar) | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة | |
| EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
| MX2020004666A (es) | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. | |
| MX389545B (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| EA201791363A1 (ru) | Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2 | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| MX2017005042A (es) | Formas de dosificacion oral de magnesio de liberacion controlada, de alta carga y metodos para elaborar y utilizar las mismas. | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| MX375924B (es) | Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |